The innate immune system is designed as an early defense system that recognizes and clears potential microbial invaders. The coagulation system co-evolved with the innate immune system from a common ancestral cellular origin, and these two systems continue to exhibit a remarkable degree of integration in their signaling pathways and regulatory circuits following tissue injury and microbial invasion. Inflammatory mediators generate procoagulant signals and intravascular thrombosis activates multiple components of the innate immune system. The success of recombinant human activated protein C for the treatment of human septic shock is likely attributable to its combined effects as an endogenous anticoagulant and an anti-inflammatory molecule. Further advances in the management of severe infections may accrue with a better understanding of the integral link between coagulation and innate immunity.
Opal SM, Esmon CTFunctional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care2003; 7: 23—38.
2.
Levi M., ten Cate H.Disseminated intravascular coagulation. N Engl J Med1999; 341: 586—592.
3.
O'Neill LA, Greene C.signal transduction pathway is activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol1998; 63: 650—-657.
4.
Opal SM, Huber CEThe Toll-like receptors and their role in septic shock. Crit Care2002; 6: 125—136.
5.
Opal SMThe phylogeneticrelationships between the coagulation system and the inflammatory networks. Crit Care Med2000; 28: S77—S82.
6.
Van Gorp Ecm , Suharti C., ten Cate H. et al. Review: infectious diseases and coagulation disorders. J Infect Dis1999; 180: 176—186.
7.
Mavrommatis AC, Theodoris T. Orfanidou A, Roussos C., Christopoulou-KokkinouV, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med2000; 28: 451—457.
8.
Esmon CTAre natural anticoagulants candidates for modulating the inflammatory response to endotoxin?Blood2000; 96: 1113—1116.
9.
Murakami K., Okajima K., Uchida M. et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol1997; 272: L197-L202.
10.
Bernard GR, Vincent J-L., Laterre P-F. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med2001; 344: 699—709.
11.
Pixley RA, De La Cadena R., Page JD et al. The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia. J Clin Invest1993; 91: 61—70.
12.
Beutler B.Sepsis begins at the interface of pathogen and host. Biochem Soc Trans2001; 29: 853—859.
13.
Lauener RP, Bircher T., Adamski J. et al. Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children. Lancet2002; 360: 465—466.
14.
Bach J-F.Mechanisms of disease: the effect of infections on the susceptibility to autoimmune and allergic diseases. N Engl J Med2002; 347: 911—920.
15.
Van der Poll T., Levi M., Hack E. et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med1994; 179: 1253—1259.
16.
Kahn ML, Nakanishi-Matsue M., Shapiro MJ, Ishihara H., Coughlin SRProtease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest1999; 103: 879—887.
17.
Riewald M., Kravchenko VV, Petrovan RJ et al. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor-1. Blood2001 ; 97: 3109—3116.
18.
Johnson K., Choi Y., DeGroot E., Samuels I., Creasey A., Aarden L.Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol1998; 160: 5130—5135.
19.
Stouthard JM , Levi M., Hack CE et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost1996; 76: 738—742.
20.
Dunzendorfer S., Kaneider N., Rabensteiner A. et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood2001; 97: 1079—1085.
21.
Enkhbaatar P., Okajima K., Murarkami K. et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med2000; 162: 1752—1759.
22.
Yuksel M., Okajima K., Uchiba M., Horiuchi S., Okabe H.Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-a production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. Thromb Haemost2002; 88: 267—273.
23.
Riewald M., Petrovan RJ, Donner A., Mueller BM, Ruf W.Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science2002; 296: 1880—1882.
24.
Conway EM, Van de Wouwer M., Pollefeyt S. et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor-κB and mitogen-activated protein kinase pathways. J Exp Med2002; 196: 565—577.
25.
Kurosawa S. , Esmon CT, Stearns-Kurosawa DJThe soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol2000; 165: 4697—4703.
26.
Loppnow H., Bil R., Hirt S. et al. Platelet-derived interleukin-1 induces cytokine production but nor proliferation of human vascular smooth muscle cells. Blood1998; 91: 134—141.
27.
Henn V., Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature1998 ; 391: 591—594.
